In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer

被引:55
作者
Israeli, O
Goldring-Aviram, A
Rienstein, S
Ben-Baruch, G
Korach, J
Goldman, B
Friedman, E [1 ]
机构
[1] Chaim Sheba Med Ctr, Susanne Levy Gertner Oncogenet Unit, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Danek Gertner Inst Genet, IL-52621 Tel Hashomer, Israel
[3] Chaim Sheba Med Ctr, Dept Gynecol Oncol, IL-52621 Tel Hashomer, Israel
[4] Tel Aviv Univ, Sackler Sch Med, Ramat Aviv, Israel
关键词
D O I
10.1016/j.cancergencyto.2004.11.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer, the leading cause of death due to gynecological malignancy, is diagnosed in most cases at an advanced stage. Combined with the paucity of symptoms of early-stage disease, the need to develop novel effective markers for the detection of potentially curable, early-stage disease is self-evident. Comprehensive analyses of somatic gene expression patterns in ovarian cancer were reported previously (n = 17) and yielded substantial information on somatically altered genes, information that can potentially be useful in developing early detection markers. To further substantiate the role that these genes play in ovarian cancer tumorogenesis, we surveyed these reports and arranged the significantly altered genes from all reported studies by their chromosomal location (in silico chromosomal clustering). Subsequent comparison of this clustering to known genomic somatic alterations at the DNA level from data obtained using comparative genomic hybridization (CGH) was carried out. The major chromosomal regions that displayed overexpressed genes were correlated with the major CGH-detectable DNA amplification areas at 20q (harboring HE4, SLP1, MYBL2, UBE2C, and SDC4) and 1q (harboring MUC1). These genes may provide insights into ovarian cancer pathogenesis and may also prove to be useful as early detection tools. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 73 条
[1]   Predicting biomarkers for ovarian cancer using gene-expression microarrays [J].
Adib, TR ;
Henderson, S ;
Perrett, C ;
Hewitt, D ;
Bourmpoulia, D ;
Ledermann, J ;
Boshoff, C .
BRITISH JOURNAL OF CANCER, 2004, 90 (03) :686-692
[2]  
ALESSI DR, 1993, ONCOGENE, V8, P2015
[3]   Whole-genome expression analysis: challenges beyond clustering [J].
Altman, RB ;
Raychaudhuri, S .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2001, 11 (03) :340-347
[4]  
*AM CANC SOC INC, 2003, CANC FACTS FIG 2003, P15
[5]  
Bayani J, 2002, CANCER RES, V62, P3466
[6]   INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE [J].
BEREK, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :675-677
[7]   DNA arrays in clinical oncology: Promises and challenges [J].
Bertucci, F ;
Viens, P ;
Tagett, R ;
Nguyen, C ;
Houlgatte, R ;
Birnbaum, D .
LABORATORY INVESTIGATION, 2003, 83 (03) :305-316
[8]  
Boman F, 2001, J PATHOL, V193, P339, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH798>3.0.CO
[9]  
2-9
[10]   The use and analysis of microarray data [J].
Butte, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (12) :951-960